Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
Verified date | May 2024 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).
Status | Active, not recruiting |
Enrollment | 328 |
Est. completion date | March 31, 2025 |
Est. primary completion date | September 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Principal inclusion criteria : - Subjects with histologically- or cytologically-documented NSCLC - Locally advanced, unresectable (Stage III) NSCLC - World Health Organisation (WHO) performance status 0-1 - At least one measurable lesion, not previously irradiated - Must have a life expectancy of at least 12 weeks at randomization Principal exclusion criteria : - Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs. - Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines. - History of allogeneic organ transplantation - Active or prior documented autoimmune or inflammatory disorders - Uncontrolled intercurrent illness - History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency - Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus - Mixed small cell and NSCLC histology - Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling - Known allergy or hypersensitivity to any of the IPs or any of the IP excipients. - Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving =20 Gy in total (V20) of more than 35% of lung volume. |
Country | Name | City | State |
---|---|---|---|
Brazil | Research Site | Barretos | |
Brazil | Research Site | Curitiba | |
Brazil | Research Site | Florianópolis | |
Brazil | Research Site | Fortaleza | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Ribeirão Preto | |
Brazil | Research Site | Ribeirão Preto | |
Brazil | Research Site | São José do Rio Preto | |
Brazil | Research Site | Sao Paulo | |
Czechia | Research Site | Brno | |
Czechia | Research Site | Ostrava | |
Czechia | Research Site | Praha 2 | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Gyor | |
Hungary | Research Site | Gyula | |
Hungary | Research Site | Törökbálint | |
India | Research Site | Bangalore | |
India | Research Site | Chennai | |
India | Research Site | Gurgaon | |
India | Research Site | Karamsad | |
India | Research Site | Mumbai | |
India | Research Site | Nasik | |
India | Research Site | New Delhi | |
India | Research Site | Vadodara | |
Japan | Research Site | Bunkyo-ku | |
Japan | Research Site | Fukuoka-shi | |
Japan | Research Site | Koto-ku | |
Japan | Research Site | Kyoto | |
Japan | Research Site | Nagoya-shi | |
Japan | Research Site | Osakasayama | |
Japan | Research Site | Sendai-shi | |
Japan | Research Site | Yokohama-shi | |
Korea, Republic of | Research Site | Busan | |
Korea, Republic of | Research Site | Chungcheongbuk-do | |
Korea, Republic of | Research Site | Gyeongsangnam-do | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Mexico | Research Site | Aguascalientes | |
Mexico | Research Site | Guadalajara | |
Mexico | Research Site | Mérida | |
Mexico | Research Site | México | |
Mexico | Research Site | Mexico City | |
Mexico | Research Site | Orizaba | |
Peru | Research Site | La Libertad | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Philippines | Research Site | Cebu City | |
Philippines | Research Site | Iloilo | |
Philippines | Research Site | Iloilo City | |
Philippines | Research Site | Makati | |
Philippines | Research Site | Manila | |
Philippines | Research Site | Quezon City | |
Philippines | Research Site | Taguig City | |
Poland | Research Site | Bydgoszcz | |
Poland | Research Site | Elblag | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Olsztyn | |
Poland | Research Site | Warszawa | |
Russian Federation | Research Site | Arkhangelsk | |
Russian Federation | Research Site | Chelyabinsk | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Omsk | |
Russian Federation | Research Site | Rostov-on-Don | |
Russian Federation | Research Site | Saint-Petersburg | |
Thailand | Research Site | Bangkok | |
Thailand | Research Site | Bangkok | |
Thailand | Research Site | Hat Yai | |
Thailand | Research Site | Khon Kaen | |
Thailand | Research Site | Mueang | |
Turkey | Research Site | Ankara | |
Turkey | Research Site | Ankara | |
Turkey | Research Site | Antalya | |
Turkey | Research Site | Diyarbakir | |
Turkey | Research Site | Istanbul | |
Turkey | Research Site | Izmir | |
Vietnam | Research Site | Hanoi | |
Vietnam | Research Site | Hanoi | |
Vietnam | Research Site | Ho Chi Minh | |
Vietnam | Research Site | Ho Chi Minh city |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Brazil, Czechia, Hungary, India, Japan, Korea, Republic of, Mexico, Peru, Philippines, Poland, Russian Federation, Thailand, Turkey, Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events | From the date of randomization until disease progression, assessed up to 4 years. | ||
Primary | Progression-free survival (PFS) | From date of randomization until the date of objective disease progression or death, assessed up to 4 years. | ||
Secondary | Overall Survival (OS) | From the date of randomization until death due to any cause, assessed up to 4 years. | ||
Secondary | Objective Response Rate (ORR) | From the date of Randomisaton until the date of objective disease progression or death, assessed up to 4 years | ||
Secondary | Overall Survival at 24 months | From the date of randomization until 24 months | ||
Secondary | Rate of complete response | From the date of Randomisaton until the date of objective disease progression or death, assessed up to 4 years | ||
Secondary | Duration of response (DoR) | From the date of first documented response (RECIST 1.1.) until the first date of documented progression or death in the absence of disease progression, assessed up to 4 years. | ||
Secondary | Disease Control Rate (DCR) | From the date of randomization until 24 weeks. | ||
Secondary | Time from randomization to second progression PFS2 | From the date of randomization to the earliest progression event subsequent to that used for the PFS endpoint or death, up to 4 years | ||
Secondary | Time to death or distant metastasis (TTDM) | From the date of randomization to until the first date of distant metastasis or death in the absence of distant metastasis, assessed up to 4 years | ||
Secondary | Presence of ADA for durvalumab in combination with CRT | From the date of randomization until 6 months after date of last IP dose. | ||
Secondary | To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using EORTC QLQ-C30 v3 | From the date of randomisation until PFS2. | ||
Secondary | To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using QLQ-LC13 | From the date of randomisation until PFS2. | ||
Secondary | To assess the PK of durvalumab in blood (peak trough concentration) when in combination with CRT | From the date of randomization until 3 months after date of last IP dose. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |